We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Blocking PD-1 Receptors Revitalizes T Cells

By Biotechdaily staff writers
Posted on 22 Jan 2006
Researchers have identified the mechanism that causes the immune system's main line of defense, CD8 T cells, to become tolerant of chronic viral infections and have found a way to revitalize them and return them to the fray.

Investigators at the Dana Farber Cancer Institute (Boston, MA, USA) and Emory University (Atlanta, GA, USA) worked with a mouse model. More...
They used a microarray system to analyze the genome of "exhausted” CD8 T cells from animals infected with chronic lymphocytic choriomeningitis virus (LCMV). The gene scan was compared to that obtained from CD8 T cells from normal mice. They found that the PD-1 gene was much more active in the exhausted cells. This result was in accord with previous findings that binding of PD-L1 protein by the PD-1 receptor caused a weakening of immune system response.

Monoclonal antibodies were prepared that bound specifically to the PD-1 receptor and prevented the binding of PD-L1. These antibodies were administered to both chronically infected wild type mice and to mice lacking CD4 T "helper” cells. Results published in the December 28, 2005, online edition of Nature showed that in both cases, blockade of the PD-1/PD-L1 inhibitory pathway had a beneficial effect on the "helpless” CD8 T cells, restoring their ability to undergo proliferation, secrete cytokines, kill infected cells, and decrease viral load. Blocking the CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) inhibitory pathway had no effect on either T cell function or viral control.

"The potential applications of this work are wide-ranging,” said contributing author Dr. Gordon Freedman, associate professor of medicine at the Dana Farber Cancer Institute. "CD8 T cells that have fought viral infections retain a ‘memory' of the viruses they have encountered, so they can rapidly respond to new infections from those viruses. We found that exhausted CD8 T cells in mice have unusually large numbers of PD-1 receptors, and blocking the PD-1/PD-L1 bond reactivated the cells' response to infection.”




Related Links:
Dana Farber Cancer Institute
Emory University

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Blood Test Measuring Tumor Proliferation May Guide Treatment Sequencing in Metastatic Melanoma

Metastatic melanoma remains difficult to manage because outcomes vary widely and early prognostic markers are limited. About half of patients carry a BRAF gene mutation, giving clinicians several first-line... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Comprehensive Genomic Testing Expands Treatment Options for Advanced Cancers

Selecting effective therapies for advanced cancers remains difficult because standard tumor testing often targets only a limited set of genes. As options dwindle, many patients face decisions without strong... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.